Moyamoya disease: diagnosis and interventions
暂无分享,去创建一个
G. Steinberg | A. Koizumi | E. Tournier-Lasserve | M. Ihara | O. Bang | T. Yoshimoto | Hatasu Kobayashi | Wanyang Liu | Yorito Hattori | Hiroyuki Ishiyama | S. Miyawaki | Tim Clausen | Yumi Yamamoto
[1] M. Vikkula,et al. Recalibrating vascular malformations and mechanotransduction by pharmacological intervention , 2022, The Journal of clinical investigation.
[2] S. Kuroda,et al. 2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society , 2022, Neurologia medico-chirurgica.
[3] B. Neel,et al. MMD-associated RNF213 SNPs encode dominant-negative alleles that globally impair ubiquitylation , 2022, Life Science Alliance.
[4] R. Tamargo,et al. Revascularization of Hemorrhagic Moyamoya Disease in a North American Cohort: The Role of Timing in Perioperative and Long-Term Outcomes , 2022, Neurosurgery.
[5] C. Ogilvy,et al. Asymptomatic moyamoya disease in a North American adult cohort. , 2022, World neurosurgery.
[6] Jing Zhao,et al. A meta‐analysis of comparisons of various surgical treatments for moyamoya diseases , 2021, Brain and behavior.
[7] K. Ogasawara,et al. Five-Year Outcomes of Medical Management Alone for Adult Patients with Ischemic Moyamoya Disease without Cerebral Misery Perfusion , 2021, Cerebrovascular Diseases.
[8] O. Akel,et al. Experimental animal models for moyamoya disease and treatment: a pathogenesis-oriented scoping review. , 2021, Neurosurgical focus.
[9] Akinobu Ota,et al. Transcriptome-wide analysis of intracranial artery in patients with moyamoya disease showing upregulation of immune response, and downregulation of oxidative phosphorylation and DNA repair. , 2021, Neurosurgical Focus.
[10] Min S. Park,et al. Experimental animal models for the study of moyamoya disease. , 2021, Neurosurgical focus.
[11] Qian Zhang,et al. The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial. , 2021, Neurosurgical focus.
[12] T. Kawaguchi,et al. The association between the Moyamoya disease susceptible gene RNF213 variant and incident cardiovascular disease in a general population: the Nagahama study , 2021, Journal of hypertension.
[13] N. Saito,et al. Differences in Clinical Features among Different Onset Patterns in Moyamoya Disease , 2021, Journal of clinical medicine.
[14] Amber N. Stratman,et al. DIAPH1 Variants in Non-East Asian Patients With Sporadic Moyamoya Disease. , 2021, JAMA neurology.
[15] K. Knobeloch,et al. Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity , 2021, Nature Communications.
[16] Elsje G. Otten,et al. Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection , 2021, Nature.
[17] T. Tominaga,et al. Dysregulation of Rnf 213 gene contributes to T cell response via antigen uptake, processing, and presentation , 2021, Journal of cellular physiology.
[18] T. Clausen,et al. E3 ubiquitin ligase RNF213 employs a non-canonical zinc finger active site and is allosterically regulated by ATP , 2021, bioRxiv.
[19] H. Hakonarson,et al. A new syndrome of moyamoya disease, kidney dysplasia, aminotransferase elevation, and skin disease associated with de novo variants in RNF213 , 2021, American journal of medical genetics. Part A.
[20] Aman B Patel,et al. Direct vs Indirect Revascularization in a North American Cohort of Moyamoya Disease , 2021, Neurosurgery.
[21] J. Saver,et al. Association of Antiplatelet Therapy, Including Cilostazol, With Improved Survival in Patients With Moyamoya Disease in a Nationwide Study , 2021, Journal of the American Heart Association.
[22] Seung-Chyul Hong,et al. Prospective Screening of Extracranial Systemic Arteriopathy in Young Adults with Moyamoya Disease , 2020, Journal of the American Heart Association.
[23] Rong Wang,et al. Characteristics of cognitive impairment in adult asymptomatic moyamoya disease , 2020, BMC Neurology.
[24] M. L. Dell'Acqua,et al. Vascular Remodeling in Moyamoya Angiopathy: From Peripheral Blood Mononuclear Cells to Endothelial Cells , 2020, International journal of molecular sciences.
[25] S. Tsuji,et al. Comprehensive investigation of RNF213 nonsynonymous variants associated with intracranial artery stenosis , 2020, Scientific Reports.
[26] D. Haselbach,et al. Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism. , 2020, eLife.
[27] B. Bender,et al. Arterial wall contrast enhancement in progressive moyamoya disease. , 2020, Journal of Neurosurgery.
[28] N. Saito,et al. Association Between the Onset Pattern of Adult Moyamoya Disease and Risk Factors for Stroke , 2020, Stroke.
[29] Seung-Chyul Hong,et al. Moyamoya Disease and Spectrums of RNF213 Vasculopathy , 2019, Translational Stroke Research.
[30] Yoon-Chul Kim,et al. Ring Finger Protein 213 Variant and Plaque Characteristics, Vascular Remodeling, and Hemodynamics in Patients With Intracranial Atherosclerotic Stroke: A High‐Resolution Magnetic Resonance Imaging and Hemodynamic Study , 2019, Journal of the American Heart Association.
[31] K. Houkin,et al. Characteristics of Moyamoya Disease Based on National Registry Data in Japan. , 2019, Stroke.
[32] M. Gitlin,et al. Psychiatric Comorbidity in Moyamoya Disease and Preliminary Guidelines For Treatment. , 2019, The American journal of psychiatry.
[33] H. Tan,et al. Rare RNF213 variants and the risk of intracranial artery stenosis/occlusion disease in Chinese population: a case-control study , 2019, BMC Medical Genetics.
[34] Lei Feng,et al. Epidemiology, diagnosis and treatment of moyamoya disease. , 2019, Experimental and therapeutic medicine.
[35] S. Kuroda,et al. Longitudinal anterior-to-posterior shift of collateral channels in patients with moyamoya disease: an implication for its hemorrhagic onset. , 2019, Journal of neurosurgery.
[36] K. Ogasawara,et al. Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients with ischemic moyamoya disease: subanalysis of a prospective cohort , 2019, Neurological research.
[37] U. Klose,et al. Hypercapnic BOLD MRI compared to H215O PET/CT for the hemodynamic evaluation of patients with Moyamoya Disease , 2019, NeuroImage: Clinical.
[38] S. Kuroda,et al. High rebleeding risk associated with choroidal collateral vessels in hemorrhagic moyamoya disease: analysis of a nonsurgical cohort in the Japan Adult Moyamoya Trial. , 2019, Journal of neurosurgery.
[39] Y. Kamatani,et al. Moyamoya Disease Susceptibility Variant RNF213 p.R4810K Increases the Risk of Ischemic Stroke Attributable to Large-Artery Atherosclerosis. , 2019, Circulation.
[40] F. Gao,et al. TPO-Ab plays a role in arterial remodeling in patients with intracranial stenosis. , 2019, Atherosclerosis.
[41] Wanyang Liu,et al. RNF213 p.R4810K Polymorphism and the Risk of Moyamoya Disease, Intracranial Major Artery Stenosis/Occlusion, and Quasi-Moyamoya Disease: A Meta-Analysis. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[42] K. Yamashita,et al. 4D ASL-based MR angiography for visualization of distal arteries and leptomeningeal collateral vessels in moyamoya disease: a comparison of techniques , 2018, European Radiology.
[43] Takeshi Kimura,et al. Rare variants in RNF213, a susceptibility gene for moyamoya disease, are found in patients with pulmonary hypertension and aggravate hypoxia-induced pulmonary hypertension in mice , 2018, Pulmonary circulation.
[44] H. Iida,et al. Dysregulation of RNF213 promotes cerebral hypoperfusion , 2018, Scientific Reports.
[45] W. Dai,et al. Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review , 2017, Environmental Health and Preventive Medicine.
[46] K. Houkin,et al. Novel insights into symptomatology of moyamoya disease in pediatric patients: survey of symptoms suggestive of orthostatic intolerance. , 2017, Journal of neurosurgery. Pediatrics.
[47] E. Génin,et al. Rare RNF213 variants in the C-terminal region encompassing the RING-finger domain are associated with moyamoya angiopathy in Caucasians , 2017, European Journal of Human Genetics.
[48] S. Miyamoto,et al. Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease , 2017, PloS one.
[49] Lanbing Yu,et al. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance. , 2017, Journal of neurosurgery.
[50] M. Brozman,et al. RNF213 Rare Variants in Slovakian and Czech Moyamoya Disease Patients , 2016, PloS one.
[51] D. Nickerson,et al. Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension , 2016, Clinical genetics.
[52] Yufang Wang,et al. Mutation of rnf213a by TALEN causes abnormal angiogenesis and circulation defects in zebrafish , 2016, Brain Research.
[53] Seung-Chyul Hong,et al. A Polymorphism in RNF213 Is a Susceptibility Gene for Intracranial Atherosclerosis , 2016, PloS one.
[54] Kazumichi Yoshida,et al. Periventricular anastomosis in moyamoya disease: detecting fragile collateral vessels with MR angiography. , 2016, Journal of neurosurgery.
[55] Seung-Chyul Hong,et al. Determinants of Basal Collaterals in Moyamoya Disease: Clinical and Genetic Factors , 2016, European Neurology.
[56] G. Zaharchuk,et al. Acute Preoperative Infarcts and Poor Cerebrovascular Reserve Are Independent Risk Factors for Severe Ischemic Complications following Direct Extracranial-Intracranial Bypass for Moyamoya Disease , 2016, American Journal of Neuroradiology.
[57] P. Ferroli,et al. Vasculogenic and Angiogenic Pathways in Moyamoya Disease. , 2016, Current medicinal chemistry.
[58] A. van der Zwan,et al. Research Progresses in Understanding the Pathophysiology of Moyamoya Disease , 2016, Cerebrovascular Diseases.
[59] H. Augustin,et al. Endothelial RSPO3 Controls Vascular Stability and Pruning through Non-canonical WNT/Ca(2+)/NFAT Signaling. , 2016, Developmental cell.
[60] S. Kuroda,et al. Significance of the Hemorrhagic Site for Recurrent Bleeding: Prespecified Analysis in the Japan Adult Moyamoya Trial , 2016, Stroke.
[61] Jong S. Kim. Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis , 2016, Journal of stroke.
[62] A. Koizumi,et al. A new horizon of moyamoya disease and associated health risks explored through RNF213 , 2015, Environmental Health and Preventive Medicine.
[63] N. Mikuni,et al. Vascular remodeling of the circle of Willis in moyamoya disease , 2015, Neurological research.
[64] T. Noguchi,et al. Noninvasive method for mapping CVR in moyamoya disease using ASL-MRI. , 2015, European journal of radiology.
[65] P. Vajkoczy,et al. Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians , 2015, European journal of neurology.
[66] S. Kuroda. Asymptomatic Moyamoya Disease: Literature Review and Ongoing AMORE Study , 2015, Neurologia medico-chirurgica.
[67] S. Miyamoto,et al. Cognitive Dysfunction Survey of the Japanese Patients with Moyamoya Disease (COSMO-JAPAN Study): Study Protocol , 2015, Neurologia medico-chirurgica.
[68] D. Hervé,et al. The Application of Clinical Genetics Dovepress Moyamoya Disease and Syndromes: from Genetics to Clinical Management , 2022 .
[69] Seung-Chyul Hong,et al. High-Resolution Magnetic Resonance Wall Imaging Findings of Moyamoya Disease , 2014, Stroke.
[70] S. Kuroda,et al. Effects of Extracranial–Intracranial Bypass for Patients With Hemorrhagic Moyamoya Disease: Results of the Japan Adult Moyamoya Trial , 2014, Stroke.
[71] T. Tominaga,et al. Temporal profile of the vascular anatomy evaluated by 9.4-T magnetic resonance angiography and histopathological analysis in mice lacking RNF213: A susceptibility gene for moyamoya disease , 2014, Brain Research.
[72] B. Reizis,et al. The role of dendritic cells in autoimmunity , 2013, Nature Reviews Immunology.
[73] A. Butte,et al. Immune response profiling identifies autoantibodies specific to Moyamoya patients , 2013, Orphanet Journal of Rare Diseases.
[74] S. Takashima,et al. Ablation of Rnf213 retards progression of diabetes in the Akita mouse. , 2013, Biochemical and biophysical research communications.
[75] S. Nanayakkara,et al. P.R4810K, a polymorphism of RNF213, the susceptibility gene for moyamoya disease, is associated with blood pressure , 2013, Environmental Health and Preventive Medicine.
[76] A. Mukasa,et al. Identification of a Genetic Variant Common to Moyamoya Disease and Intracranial Major Artery Stenosis/Occlusion , 2012, Stroke.
[77] M. Guan,et al. Molecular Analysis of RNF213 Gene for Moyamoya Disease in the Chinese Han Population , 2012, PloS one.
[78] T. Hirai,et al. Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3D constructive interference in steady-state MR image: is arterial constrictive remodeling a major pathogenesis? , 2012, Acta Neurochirurgica.
[79] A. Koizumi,et al. Distribution of moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations. , 2012, Neurologia medico-chirurgica.
[80] Y. Kuroiwa,et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease , 2012, Neurology.
[81] A. Fujiyama,et al. Identification of RNF213 as a Susceptibility Gene for Moyamoya Disease and Its Possible Role in Vascular Development , 2011, PloS one.
[82] Hong Yang,et al. Increased Thyroid Function and Elevated Thyroid Autoantibodies in Pediatric Patients With Moyamoya Disease: A Case-Control Study , 2011, Stroke.
[83] G. Zhu,et al. Phenotype Switch of Vascular Smooth Muscle Cells After siRNA Silencing of Filamin , 2011, Cell Biochemistry and Biophysics.
[84] M. Lee,et al. Movement disorders associated with moyamoya disease: A report of 4 new cases and a review of literatures , 2010, Movement disorders : official journal of the Movement Disorder Society.
[85] Seung-Chyul Hong,et al. Association of Thyroid Autoantibodies With Moyamoya-Type Cerebrovascular Disease: A Prospective Study , 2010, Stroke.
[86] R. Scott,et al. Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.
[87] S. Kuroda,et al. Moyamoya disease: current concepts and future perspectives , 2008, The Lancet Neurology.
[88] Hidenao Fukuyama,et al. Microbleeds in Moyamoya Disease: Susceptibility-Weighted Imaging Versus T2*-Weighted Imaging at 3 Tesla , 2008, Investigative radiology.
[89] K. Ikeda,et al. Asymptomatic Moyamoya disease. , 2007, Stroke.
[90] H. Seol,et al. Headache in pediatric moyamoya disease: review of 204 consecutive cases. , 2005, Journal of neurosurgery.
[91] D. Tirschwell,et al. Moyamoya disease in Washington State and California , 2005, Neurology.
[92] N. Sakai,et al. Studies on cytomegalovirus and Epstein-Barr virus infection in Moyamoya disease , 1997, Clinical Neurology and Neurosurgery.
[93] S. Miyamoto,et al. Cerebral revascularization using omental transplantation for childhood moyamoya disease. , 1993, Journal of neurosurgery.
[94] S. Miyamoto,et al. Study of the posterior circulation in moyamoya disease. Part 2: Visual disturbances and surgical treatment. , 1984, Journal of neurosurgery.
[95] S. Kuroda,et al. Revision 2021 of The Guideline for The Diagnosis of Moyamoya Disease by Research Committee on Moyamoya Disease (Spontaneous Occlusion of Circle of Willis) , 2022, Surgery for Cerebral Stroke.
[96] Tej D. Azad,et al. Validation and Application for the Berlin Grading System of Moyamoya Disease in Adult Patients. , 2019, Neurosurgery.
[97] A. Hata,et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene , 2011, Journal of Human Genetics.